{
    "url_original": "https://www.wsj.com/articles/roche-licenses-rights-to-experimental-eye-cell-therapy-11639994404?mod=business_lead_pos3",
    "url": "roche-licenses-rights-to-experimental-eye-cell-therapy-11639994404",
    "title": "Roche Licenses Rights to Experimental Eye Cell Therapy",
    "sub_head": "Lineage drug is in early clinical testing for an eye condition that can cause blindness but doesn’t have an approved treatment",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-454783?width=860&height=573",
    "image_1": "im-454783.jpg",
    "time": "2021-12-20 05:00:00",
    "body": "Roche Holding AG  is adding an experimental drug for a blinding eye condition in a deal aimed at helping the company move further into cell-based therapies.<br />Roche’s Genentech drugs business said Monday that it has bought the rights to the eye drug from  Lineage Cell Therapeutics Inc.  for $50 million cash upfront and additional payments in the future if development, regulatory and sales milestones are met."
}